Industry News

Allergan plc, a leading global pharmaceutical company, and Gedeon Richter Plc., today provided a clinical and regulatory update on cariprazine. For more than a decade both companies have conducted over 20 clinical trials enrolling thousands of patients worldwide to evaluate the efficacy and safety of cariprazine for patients suffering from a broad range of mental health illnesses. Cariprazine was approved by the..."/>
Allergan and Richter Provide Update on Cariprazine Program
ScinoPharm Taiwan, Ltd and CVie Therapeutics Limited jointly announced the initiation of a discovery and development collaboration to identify the new generation compound to Istaroxime, CVie's acute heart failure treatment currently in late Phase IIb trials in Italy and China. This collaboration marks the first time for ScinoPharm to collaborate with an external partner, CVie, from a discovery perspective. According to the agreement,..."/>
ScinoPharm and CVie Therapeutics Limited to Jointly Develop New Heart Failure Drug
Regeneron Pharmaceuticals, Inc.."/>
Adicet Bio teams with US biotech giant Regeneron [Globes, Tel Aviv, Israel]
Sexual wellness brand Japani up for sale [Mint, New Delhi]
Fortis Healthcare Ltd's net profit more than tripled in the quarter ended 30 June as it admitted more patients and earned more per occupied bed, the company said on Thursday. Net profit rose to Rs.15.1 crore in the three months from Rs.4 crore in year-earlier period. Revenue rose 9% to Rs.910 crore in the same period."/>
BRIEF: Fortis Healthcare's June quarter profit more than triples to Rs15.1 crore [Mint, New Delhi]
Derma Sciences Inc. of Princeton, New Jersey, disclosed last week it had acquired BioD LLC for $21.3 million up front and potentially nearly $78 million. On Thursday, BioD chief executive Russell Olsen outlined future prospects for the 50-..."/>
Memphis firm that turns placentas into healing product plans to expand [The Commercial Appeal, Memphis, Tenn.]
Collegium Pharmaceutical, Inc. announced today that the Company will host a conference call and live audio webcast on Wednesday, August 10, 2016 at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a corporate update.. To access the conference call, please dial 698-6931 or 905-2993."/>
Collegium to Host Conference Call to Discuss Second Quarter 2016 Financial Results and Provide Corporate Update
M and A Navigator: Deal pipeline –4 August
Egalet Corp., is one of more than a dozen abuse-deterrent formulations being developed by companies for oxycodone, hydrocodone, and morphine, which is now a top priority by the U.S. Shares of Egalet rose 8 percent on the news to close at $7.62."/>
FDA panel recommends approval of Egalet abuse-deterrent opioid [The Philadelphia Inquirer]
Chartwell Retirement Residences announced today its results for the three and six months ended June 30, 2016.. Total adjusted funds from operations up $5.7 million or 16.6% Same property net operating income up $4.2 million or 8.4% Same property occupancy increased 1.6 percentage points to 93.4%. "Following our strong first quarter 2016 performance, our operating platforms delivered excellent results in Q2 2016 with solid growth in same property..."/>
Chartwell Announces Second Quarter 2016 Results
Arbutus Biopharma Corporation, an industry-leading Hepatitis B Virus therapeutic solutions company, today announced its second quarter 2016 unaudited financial results and provided a corporate update.. "We are on track to deliver clinical data from our lead HBV program ARB-1467 in the second half of this year."/>
Arbutus Provides Corporate Update and Announces Second Quarter 2016 Financial Results
Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, and NAFLD/NASH today announced the pricing of its initial public offering of 3,000,000 shares of its common stock at a price to the public of $10.00 per share. The shares are expected to..."/>
Gemphire Therapeutics Announces Pricing of Initial Public Offering
CRH Medical Corporation, a North American medical company that provides physicians with innovative services and products for the treatment of gastrointestinal diseases, announces that it is scheduled to present at the upcoming Canaccord Genuity 36th Annual Growth Conference in Boston, MA. Edward Wright, Chief Executive Officer of CRH Medical will be presenting on Wednesday, August 10th 2016 at 1:30pm.. CRH Medical Corporation is a..."/>
CRH Medical Corporation to Present at the Canaccord Genuity Growth Conference
Fortive, core sales at Tektronix were down by percentages in the high single digits, according to the company, "broadly reflecting weak semiconductor and consumer electronics activity outside of China." The weak quarter was no surprise-- Tektronix has been a big disappointment since Fortive's predecessor, Danaher, bought Tektronix nearly a decade ago."/>
What's it going to take to fix Tektronix? [The Oregonian, Portland, Ore.]
CryoLife, Inc., a leading medical device and tissue processing company focused on cardiac surgery, announced today that it will participate in the upcoming 36 th Annual Canaccord Genuity Annual Growth Conference on Wednesday, August 10, 2016 in Boston, MA. A live webcast of the Company's presentation is scheduled to begin at 12:30 p.m. ET and will feature an overview of the company and fireside chat with Pat Mackin, Chairman, President and Chief..."/>
CryoLife to Present at 36th Annual Canaccord Genuity Growth Conference
China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the second quarter of 2016.. Second Quarter 2016 Financial Highlights. Total sales in the second quarter of 2016 increased by 23.4% in RMB terms, or 15.5% in USD terms, to $91.4 million from $79.1 million in the same quarter of 2015. Gross profit increased by 15.2% to $59.9 million from..."/>
China Biologic Reports Financial Results for the Second Quarter of 2016
CareDx, Inc., a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, presented on the analytical validation of AlloSure at the 68 th American Conference on Clinical Chemistry in Philadelphia, PA. The CareDx abstract at AACC was one of 22 selected for an oral presentation from over 800 submitted abstracts.."/>
CareDx Presents Validation of AlloSure® at AACC Conference Session on Emerging Topics in Laboratory Medicine
Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant infections, today reported financial results for the second quarter ended June 30, 2016, and provided an overview of certain corporate achievements and plans.. “During the second quarter, we finalized the protocol for IGNITE4, our upcoming phase 3 clinical trial evaluating IV eravacycline..."/>
Tetraphase Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Progress
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced that the joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration voted 18 to 1 to recommend approval of ARYMO™ ER."/>
Egalet Announces FDA Advisory Committees Recommend Approval of Abuse-Deterrent ARYMO™ ER (Morphine Sulfate) and Reports Second Quarter 2016 Financial Results
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that today it closed on a previously disclosed underwritten offering of units with gross proceeds of $9,225,000. Canaccord Genuity Inc. acted as the sole bookrunner and Roth Capital Partners, LLC acted as lead..."/>
Palatin Technologies Announces Closing of $9.2 Million Financing
Kindred Healthcare, Inc. today announced that its Board of Directors approved the payment of a cash dividend of $0.12 per common share to its common shareholders. The dividend will be paid on September 2, 2016 to common shareholders of record as of the close of business on August 18, 2016.. Kindred also today announced that its Board of Directors has approved payment in cash of the scheduled September 1, 2016 installment payment of $18.75 per share of the..."/>
Kindred Healthcare Board of Directors Declares Cash Dividend of $0.12 Per Common Share and Approves Scheduled Preferred Stock Installment Payment of $18.75 Per Preferred Share
Genesis HealthCare, one of the largest post-acute care providers in the United States, today announced operating results for the second quarter ended June 30, 2016.. Summary of Recent Financing Activity. Addresses near-term refinancing and liquidity risks by entering into a new $120 million four-year term loan agreement on July 29, 2016 and paying off the prior term loan that would have matured in December 2017; Obtains greater..."/>
Genesis Healthcare Reports Second Quarter 2016 Results

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary561 Articles
Information Technology497 Articles
Financials429 Articles
Industrials302 Articles
Health Care296 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at